Brief Description
|
|
Ibrutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK. It has given good results in two phase II clinical trials, and currently under evaluation in several phase III clinical trials.
|